Loading...

Pau Castel Morales, PhD

Title(s)Postdoctoral Scholar, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-502-1710
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The duality of human oncoproteins: drivers of cancer and congenital disorders. Nat Rev Cancer. 2020 Jul; 20(7):383-397. Castel P, Rauen KA, McCormick F. PMID: 32341551.
      View in: PubMed   Mentions:    Fields:    
    2. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Rep. 2019 04 02; 27(1):294-306.e5. Toska E, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku M, Xu G, Park J, Minuesa G, Shifman SG, Socci ND, Koche R, Leslie CS, Scaltriti M, Baselga J. PMID: 30943409.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    3. RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science. 2019 03 15; 363(6432):1226-1230. Castel P, Cheng A, Cuevas-Navarro A, Everman DB, Papageorge AG, Simanshu DK, Tankka A, Galeas J, Urisman A, McCormick F. PMID: 30872527.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    4. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discov. 2019 02; 9(2):199-209. Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY. PMID: 30463996.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    5. Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. Nat Commun. 2018 11 16; 9(1):4826. Angulo-Urarte A, Casado P, Castillo SD, Kobialka P, Kotini MP, Figueiredo AM, Castel P, Rajeeve V, Milà-Guasch M, Millan J, Wiesner C, Serra H, Muixi L, Casanovas O, Viñals F, Affolter M, Gerhardt H, Huveneers S, Belting HG, Cutillas PR, Graupera M. PMID: 30446640.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    6. Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2017 06 06; 23(6):788. Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN. PMID: 28586336.
      View in: PubMed   Mentions:    Fields:    
    7. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 03 24; 355(6331):1324-1330. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PMID: 28336670.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    8. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016 11; 22(11):1303-1313. Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN. PMID: 27775704.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    9. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J. 2016 10 17; 35(20):2263. Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR. PMID: 27798145.
      View in: PubMed   Mentions: 4     Fields:    
    10. The emerging role of serum/glucocorticoid-regulated kinases in cancer. Cell Cycle. 2017 01 02; 16(1):5-6. Castel P, Scaltriti M. PMID: 27636373.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    11. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discov. 2016 10; 6(10):1134-1147. Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. PMID: 27604488.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    12. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J. 2016 09 01; 35(17):1902-22. Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR. PMID: 27481935.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    13. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Ka Inhibition. Cancer Cell. 2016 08 08; 30(2):229-242. Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PMID: 27451907.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    14. Therapeutic Benefit of Selective Inhibition of p110a PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2016 Dec 01; 22(23):5805-5817. Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M. PMID: 27225693.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    15. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016 Mar 30; 8(332):332ra42. Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S, Scaltriti M, Antonescu CR, Baselga E, Baselga J. PMID: 27030594.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    16. The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. Elife. 2016 Jan 26; 5:e12034. Grego-Bessa J, Bloomekatz J, Castel P, Omelchenko T, Baselga J, Anderson KV. PMID: 26809587.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    17. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015 Apr 15; 7(283):283ra51. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PMID: 25877889.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    18. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature. 2015 Feb 12; 518(7538):240-4. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M. PMID: 25409150.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansAnimals
    19. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol. 2014 Jul-Sep; 1(3):e963447. Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M. PMID: 27308344.
      View in: PubMed   Mentions:
    20. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014 Mar 25; 7(318):ra29. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M. PMID: 24667376.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    Pau's Networks
    Concepts (145)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑